Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by allinenergy2on Aug 13, 2015 8:48am
122 Views
Post# 24014067

Naproxen-Is a Little or Less Poison Safe?

Naproxen-Is a Little or Less Poison Safe?Why do you continue to "fabricate and obfuscate" actual data that was derived from Phase 1 studies CasusFratuitous?

We already know that too much Naproxen can lead to internal bleeding and even death, yet Naproxen has been approved by the FDA for treatment of inflammatory disorders at lower, safer dosages.

So you tell this board, is Naproxen poisonous? If it is, why aren't you compaining to the FDA? You are a lawyer aren't you?

Phase 1 data for ATB-346 has shown COX inhibition as low as 75 mg and safety up to 250 mg doses.

So doses of 750 mg and higher can cause liver damage and that's all you concentrate on?

Read a bit about NSAIDs and you'll see that too much can cause damage, and too much of Naproxen, which ATB-346 will be compared to in Phase 2 testing, can cause internal bleeding along with death if too much is taken,yet Naproxen has been approved for quite some time by the FDA and has $Billions in annual sales.

So you think ATB-346 is a poison CasusFortuitous? That's laughable to say the least. If ATB-346 is a poison, so is Naproxen and all other NSAIDs sold over the shelf without prescription.

Good luck to all here.


CasusFortuitous obfuscates the following:

Is a little poison less damaging than a lot? Maybe, sure. Let's presume (again) that it is just so the analysis can continue...

Will the lower, less poisonous dosages be effective in reducing pain? Well, in addition to the multiple presumptions (above) that may or may not work out as you expect, we come to another roadblock to ATB-346 being the future blockbuster that you pump it to be...

Who knows whether it works in human beings to address its primary indication of reducing pain and inflammation?

Not me. Not you. Not Antibe.

The real "fact is" whether it actually works or not is anyone's guess. Claiming, as you continue to do, that ATB-346's success is a foregone conslusion is the only misleading information being posted here.
Read more at: https://www.stockhouse.com/companies/bullboard/v.ate/antibe-therapeutics-inc#9iAFfQVlfeCtl6vK.99



And here's the TRUTH From the company Presentation pg. 28 Phase 1 on humans:


https://www.antibethera.com/i/slides/150508%20Antibe%20retail%20deck%20(website).pdf

Phase 1 Summary

Integrated, adaptive SAD/MAD (single ascending dose/
multiple ascending dose) completed

96 subjects in 12 cohorts of 8 each; 8 single dose cohorts,
3 multiple dose cohorts (6 on drug, 2 on placebo per
cohort); one food-effect cohort

ATB-346 was safe and tolerable at all tested single dose
levels, and at or below 250 mg daily for 14 days. Daily
doses of ≥ 750 mg resulted subjects developing increases
in liver enzymes that appear to be dose dependent.



If you want proof that it works to suppress COX activity, the Bloom Burton Presentation is a good one to read. Can't copy and past the chart, but at 75 mg dosage, it shows the COX suppression compared to 500 mg dosage of Naproxen.

Look on pg. 25 of the presentation at the following link:

https://www.antibethera.com/i/slides/150504%20BB%20presentation.pdf









Bullboard Posts